Gold Nanoparticles - Active Enrollment

We are conducting a trial for utilizing gold nanoparticles paired with infrared laser heat. Eligible patients have to have superficial tumors. We are treating the following types:

• Dogs with large mast cell tumors (>2 cm)

• Dogs with soft tissue sarcomas (<2cm in diameter)

• Dogs with oral melanoma (2-3cm diameter)

• Dogs with cutaneous or footpad melanoma (<2cm)

• Cats with oral squamous cell carcinoma not involving the bone

• Cats with other cutaneous tumors like Mast cell tumors, Sarcomas or Carcinomas

This clinical trial utilizes gold nanoparticles in a gross disease setting.

Gold Nanoparticles are inert and are given IV to the patient and after a period of time the patient comes back to have the tumor heated with a laser. As the tumor vasculature is heated through the external near infrared spectrum of light, the gold nanoparticles are excited, the laser energy is converted to heat and the tumor vasculature is disrupted killing the tumor from the inside out.

Smaller tumors typically need only the 1 session of heat but larger tumors may need more than 1 session of heat (average 2-3 for sarcomas).

THE TRIAL IS NOW ENROLLING PATIENTS!

If you have a potential case to discuss, have a patient with a tumor in a bad location for surgery or if you would like to learn more, please contact us at 425-697-2272 for more information.

Gilvetmab paired with EGFR for Histo diagnosed Hemangiosarcoma - Active enrollment

The current clinical trial for EGFR vaccination with Yale has been granted the rights to add Gilvetmab for these patients through a MERCK Product Grant Support. Gilvetmab is only available at BARC for canine patients with Hemangiosarcoma enrolled in this trial. Gilvetmab is the first and only immune checkpoint inhibitor developed for the treatment of mast cell tumors (MCTs) and melanomas in dogs and can be used on a case by case bases for those two diseases as well. All other inquiries of Gilvetmab’s use in other disease formats should be directed at MERCK Animal Health.

 Paclitaxel for K9 Hemangiosarcoma - Active enrollment

BARC is enrolling patients in a clinical trial for a unique chemotherapy agent for splenic hemangiosarcoma patients. Paclitaxel is the drug of choice in humans with angiosarcoma and needs to be re-evaluated in dogs. Paclitaxel has historically not been well tolerated in dogs in its original formulation. This new formulation hopes to mitigate those side effects and have efficacy in this disease.

We are enrolling pet companion dogs that have been diagnosed with non-metastatic histopathologic diagnosed splenic hemangiosarcoma.

These patients will receive further staging to verify no visible metastasis are present at the time of enrollment. The drug will be given IV every 3 weeks for a total of 5 doses. Patients are allowed to be on Yunnan Baiyao but no other immunotherapies, supplements or chemotherapy.

This trial is fully funded and staging and chemotherapy visits are covered by the sponsor.

Please have your veterinarian call or email us if your patient may be a candidate for this trial as we do want to prioritize referral for these patients.

Paclitaxel for Feline Tumors -Active Enrollment

BARC is enrolling Feline patients in a clinical trial for a unique chemotherapy agent for a variety of tumor types. Paclitaxel is the drug of choice in humans with angiosarcoma and we would like to evaluate this drug and its use in feline tumors.

We are enrolling feline cancer patients that have been diagnosed with measurable tumor within or on their body.

Inclusion Criteria

• Cats with an externally measurable solid tumor of ≥ 10 mm in the long axis or an internally measurable solid tumor of ≥ 20 mm in the long axis or a lymph node measuring ≥ 15 mm in the short axis, regardless of location

• Solid tumor may be of any histological type but diagnosis must be documented via histopathology or cytopathology report

• Anticipated life expectancy > 28 days

• Acceptable physical examination with adequate organ function • Modified Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 on a scale of 0–4

• Owner consent to enrollment in the study and ability to comply with the protocol visit schedule

• Availability of non-pregnant/breast-feeding adult individuals in the household to change the litter daily for a minimum of 3 days after each treatment

Exclusion Criteria

• Cats that have received cytotoxic chemotherapy within the last 21 days

• Cats with an active systemic infection • Cats with a clinical history of constipation, megacolon, or peripheral neuropathy

• Any concurrent disease state that requires prohibited concomitant medications

• Cats that are pregnant, lactating, or intended for breeding during the study period

• Cats currently enrolled in another therapeutic clinical trial

• Inadaquate blood parameters ( bsolute neutrophil count < 2.0 x 109/L, Platelets < 75 x 109/L, Hematocrit < 25%, Creatinine > 1.5 ULN, Significant liver disease: Bilirubin > 1.5x ULN)

• Any other reason that would affect the safety of the cat or severely interfere with study procedures

These patients will receive further staging that will be funded by the trial. The drug will be given IV every 3 weeks for a total of 5 doses.

Financial Support: Fully funded. All treatments and procedures associated with the clinical trial will occur with no cost to the owner.

Trial Status: Currently Ongoing

Study for Canine Lymphoma - CLOSED

We just completed the enrollment for this novel immunotherapy in dogs with Naive B cell lymphoma or Refractory B cell lymphoma. Once the dose finding data has been evaluated we are hopeful a second arm of the trial may be available for patients with B cell lymphoma to look at efficacy.

Financial Support: Fully funded. All treatments and procedures associated with the clinical trial will occur with no cost to the owner.

Trial Status: CLOSED FOR DATA REVIEW

 Immunotherapy for Transitional Cell Carcinoma /Urothelial Carcinoma - CLOSED

This study was performed to evaluate a novel immunotherapy when used in dogs with transitional cell (TCC) or urothelial carcinoma (UC). The data is being evaluated and we are moving into the second arm of the planned combined therapy of two immunotherapy agents together. This should launch in late Spring 2025.

Financial Support: Fully funded. All treatments and procedures associated with the clinical trial will occur with no cost to the owner.

Trial Status: CLOSED FOR DATA REVIEW

Study for Canine Superficial Squamous Cell Carcinoma (SCC) - Active Enrollment

We are enrolling pet companion dogs that have been diagnosed with non-metastatic squamous cell carcinoma (SCC, a type of cancer) in a clinical trial for a newly formulated chemotherapy treatment delivered via an intratumor injection. An intratumor injection requires a much lower dose of carboplatin than required by administration systemically. Additionally, this new formulation hopes to provide long-acting local activity.

Eligibility for Dogs to Participate in the Study include but are not limited to:

· The dog is diagnosed cytologically or histologically with Squamous cell carcinoma.

· The dog has at least one lesion with a longest diameter (LD) of ≥1.0 cm that can be measured to assess response to treatment.

· The dog has no evidence of metastasis based on thoracic radiographs and cytological evaluation of local lymph nodes, and any palpably enlarged lymph nodes.

· The dog has not received prior treatment with radiation, immunotherapy, or chemotherapy for cancer.

· The dog has no renal, cardiovascular, hepatic, and/or gastrointestinal dysfunction, neutropenia, or thrombocytopenia.

· The dog has no uncontrolled systemic disorders (such as diabetes mellitus) other than SCC.

· The dog has no significant co-morbid illness, which includes but is not limited to a history of congestive heart failure or clinical coagulopathy.

Financial Support: Fully funded. All treatments and procedures associated with the clinical trial will occur with no cost to the owner.

Trial Status: Currently Ongoing

EGFR Immunotherapy - Active Enrollment

BARC continues to offer a unique immunotherapy that targets the EGFR/HER2 pathway. Epidermal Growth Factor Receptor (EGFR) is overexpressed on a number of human cancers, and often is indicative of a poor outcome.

We are hoping to induce a polyclonal anti-EGFR/HER2 tumor antigen response by vaccine therapy.

We are enrolling companion dogs with spontaneous EGFR expressing tumors to receive a series of 2 vaccines 3 weeks apart. There is another visit after vaccination to draw a blood sample for antigen response analysis. Dogs with EGFR expressing tumors will be immunized with a short peptide of the EGFR extracellular domain with sequence homology to HER2.

To receive the immunotherapy without required Oncologist consultation:

1. Referral direct from another Veterinary Specialist (Oncologist, Internist, Surgeon, etc)

2. Viable tumor types include:

• Osteosarcoma patients

• Hemangiosarcoma patients

• Transitional Cell Carcinoma

• Pulmonary Carcinoma (with records review)

• High grade Mast cell tumors (with records review)

Naive patients can also schedule to have an Oncology consult and this therapy will be discussed if applicable to your dogs disease profile.

Please contact us today for more information!